THANARA: A Microbiome-Based Skincare Innovation Featuring 4P-Biotics Technology by AL-DNA
BANGKOK, May 9, 2025 /PRNewswire/ -- A professor from Chulalongkorn University's Faculty of Science has developed a skincare formula using microbiome and 4P-biotics technology, resulting in a serum and sunscreen lotion under the brand THANARA. These products help balance the microbiome on facial skin, promoting a healthy, youthful, clear, and acne-free complexion.
Healthy, moisturized, radiant, and youthful skin is a goal for many. Achieving this not only involves "beauty from the inside out" through proper nutrition, hydration, rest, emotional well-being, and balanced exercise, but also relies on effective external skin care--where "good microorganisms" play a significant role.
"Microbiomes are microorganisms that live in our bodies and on our skin. They help maintain skin balance, support overall skin health (such as pH levels, moisture, and skin barrier function), and help prevent infections," explained Associate Professor Dr. Naraporn Somboonna. She emphasized the growing importance of microbiomes in the health and beauty industry.
"Balancing the microbiome is key to restoring healthy skin," Assoc. Prof. Dr. Naraporn shared, introducing the idea behind the innovative skincare formula under the "THANARA" brand, developed by "AL-DNA," a startup incubated by CU Innovation Hub/CU Enterprise.
Inspiration Behind the Skincare Innovation
With her expertise in microbiology and portable genetic testing, Assoc. Prof. Dr. Naraporn has created impactful innovations in various fields. In public health, she developed a three-gene COVID-19 test kit used during the pandemic. In agriculture, she designed an ASFV (African Swine Fever Virus) test kit to help farmers detect infections quickly and conveniently.
In the food industry, she introduced a Live Total Bacteria and Coliform Detections test kit to identify harmful bacteria in food and beverage production. Her interest in microbiomes extends to their roles in human and environmental health. She is also a member of the Multi-Omics for Functional Products in Food, Cosmetics, and Animals Research Unit and the Omics Sciences and Bioinformatics Center at Chulalongkorn University.
Healthy Skin Through Microbiome and 4P-Biotics Technology
According to Assoc. Prof. Dr. Naraporn, AL-DNA has launched two skincare products, both patented and FDA-certified to ensure user safety:
"What makes THANARA unique is its use of 4P-Biotics technology--Probiotics, Parabiotics, Prebiotics, and Postbiotics—to help balance the skin's microbiome," Assoc. Prof. Dr. Naraporn explained. "Moreover, THANARA products are free from potential irritants like alcohol, parabens, and silicone."
AL-DNA: The Future of Health and Beauty
THANARA products are currently available at the Faculty of Science (Research Division), CU Enterprise, and via online channels. Looking ahead, Assoc. Prof. Dr. Naraporn says that AL-DNA plans to expand its line with additional microbiome-based skincare products, including personalized skin analysis and anti-aging treatments.
For more information, please contact Assoc. Prof. Dr. Naraporn Somboonna at the Department of Microbiology, Faculty of Science, Chulalongkorn University, or reach out through CU Enterprise and CU Sci Products and Services, or call +6680-440-4509.
View the photo album of this article at https://www.chula.ac.th/en/highlight/232515/
About Chulalongkorn University
"Chulalongkorn University proudly retains its No. 1 position among Thai universities and ranks 132nd in Asia out of more than 2,000 institutions in the THE Asia University Rankings 2025—a testament to the excellence of Thai higher education on the regional stage."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
2 days ago
- Korea Herald
FutureCeuticals, Inc. Announces Peer-Reviewed Publication Highlighting Cellular Health and Immune Support Benefits of vitAlign®
MOMENCE, Ill., June 5, 2025 /PRNewswire/ -- New research published in the International Journal of Molecular Sciences shows that vitAlign®, a proprietary and comprehensive healthy aging innovation from FutureCeuticals, delivers significant benefits for restoring cellular health and supporting a healthy immune response. The study highlights vitAlign's effectiveness in regulating cellular function and metabolic imbalances associated with immune stressors—from the seasonal cold and flu to more complex environmental and immune-related challenges. Researchers evaluated the impact of a low, 50 mg dose of vitAlign in medically stable adults aged 40–55 recovering from a moderate course of COVID-19, as defined by CDC guidelines. The study compared vitAlign to a 1000 mg dose of Vitamin C, focusing on key markers and processes that directly impact immune and cellular health. Results showed that vitAlign significantly reduced excessive reactive oxygen species (ROS) production in mitochondria and through the NOX2 and iNOS pathways—key mechanisms that influence immune and cellular function. Additionally, researchers observed increased levels of circulating, bioavailable nitric oxide, suggesting support for endothelial function and cardiovascular health. The authors noted that the increase in nitric oxide is likely attributable to vitAlign's ability to regulate multiple pathways of ROS production. Notably, vitAlign delivered measurable effects within 30 minutes, lasting up to three hours. In contrast, Vitamin C, which was used as a positive control, was administered at twenty times the dose and did not demonstrate comparable broad-spectrum activity. "These findings build on over a decade of published clinical research establishing vitAlign as a significant cellular health innovation, now extended directly to immune function," said J. Randal Wexler, FutureCeuticals' General Counsel and Vice President of R&D. "Previously, we've shown that vitAlign improves cellular energy efficiency and helps restore metabolic balance, both acutely and over time." Wexler added, "These new results, which compare favorably to a well-known antioxidant like Vitamin C, reinforce vitAlign's potential as a multi-faceted phytonutrient formula, providing broad support for healthy aging, cardiovascular health, and immune function. Our partners are excited about what this means for product innovation and their customers looking for daily cellular health support." About FutureCeuticals: FutureCeuticals, Inc. is the developer of vitAlign and a leader in the research, development, and manufacture of plant-based powders and extracts for the functional food, beverage, and dietary supplement markets.
Korea Herald
3 days ago
- Korea Herald
Continuity Biosciences Acquires Focal Medical to Advance Targeted Drug Delivery for Pancreatic Cancer
BRADENTON, Fla., June 4, 2025 /PRNewswire/ -- Continuity Biosciences, LLC, a developer of advanced drug delivery technologies, announced today the acquisition of Focal Medical, Inc., a North Carolina-based biopharmaceutical company pioneering site-specific chemotherapy using iontophoresis. The acquisition represents a key step in Continuity's strategy to become a leader in device targeted therapeutics for intractable solid tumors. Founded by leading scientists and clinicians, Focal Medical has developed a proprietary platform that delivers chemotherapy directly to tumors using iontophoresis —this minimally-invasive technique utilizes a mild electrical current to drive therapeutic compounds into targeted tissues. This method enhances local drug concentration while minimizing systemic toxicity, a critical need in the treatment of pancreatic and other solid-tissue cancers. Focal Medical's lead product candidate, an iontophoresis device directed gemcitabine therapy for pancreatic cancer, has been cleared by the U.S. Food and Drug Administration (FDA) through an Investigational New Drug (IND) application. Phase 1b clinical trials are expected to begin later this year. "This is a transformative milestone for Continuity Biosciences," said Ramakrishna Venugopalan, PhD, MBA, Chief Executive Officer of Continuity Biosciences. "Focal Medical's approach to localized drug delivery aligns perfectly with our vision to improve bioavailability, reduce systemic exposure, and deliver better outcomes for patients. We are thrilled to bring this promising platform into our portfolio and into the clinic." Through the acquisition, Continuity Biosciences obtains Focal Medical's entire patent estate, iontophoresis technology platform and specialized equipment, scientific know-how, and licensing agreements with the University of North Carolina at Chapel Hill. In addition, key scientific staff and leadership from Focal will join Continuity, further enhancing its internal capabilities. A dedicated research and development facility in Cary, NC that supports ongoing platform and pipeline advancement is also part of the acquisition and will be expanded to support other delivery platforms. Visionary Founders Driving the Innovation Focal Medical was co-founded by: Their iontophoresis system is designed to deliver gemcitabine, an FDA-approved chemotherapy agent, directly into pancreatic tumors. Traditional systemic administration of gemcitabine is often limited by poor tumor penetration and significant toxicity. Focal's approach bypasses those limitations by delivering the drug directly to the tumor site with high precision and minimal systemic toxicity. "After nearly a decade of R&D, we are excited to join the Continuity Biosciences family," said Tony Voiers, Acting CEO of Focal Medical. "We are grateful to our founders, scientific collaborators, and investors who have helped us reach this pivotal point. Partnering with Continuity ensures that this novel therapy moves forward into the clinic where it has the potential to help patients facing one of the deadliest cancers." This acquisition reinforces Continuity Biosciences' commitment to building a diverse portfolio of clinically meaningful drug delivery platforms and signals a decisive move toward becoming a clinical-stage leader in site-specific therapy. About Continuity Biosciences Continuity Biosciences, LLC is a biopharmaceutical company developing advanced drug delivery technologies that address the limitations of conventional therapeutic administration. With operations in Bradenton, FL; Houston, TX; Raleigh, NC; and Torino, Italy, the company focuses on combination drug-device platforms for chronic and complex conditions. Visit:
Korea Herald
4 days ago
- Korea Herald
G-Dragon, Le Sserafim, Babymonster push on with overseas concerts amid COVID-19 surge in Asia
K-pop companies refrain from cancellations as no official restrictions are in place Despite the recent surge in the number of COVID-19 cases across parts of Asia, K-pop stars, including G-Dragon, Le Sserafim and Babymonster, are pressing ahead with their overseas concerts. According to the Korea Disease Control and Prevention Agency (KDCA) on Monday, countries including China, Thailand and Singapore have recently reported a notable increase in COVID-19 cases. While the situation in Korea remains relatively stable, the agency warned that a summer resurgence is possible due to international travel and regional outbreaks. The NB.1.8.1 variant — now dominant in the affected countries — is known for its strong transmissibility and immune-evasive properties, although its severity and fatality rate remain relatively low. The KDCA is advising high-risk travelers to these countries to get vaccinated before departure. G-Dragon of Big Bang is currently on his 'Ubermensch' world tour, performing across nine Asian cities including Taipei, Kuala Lumpur, Jakarta, Hong Kong and Bangkok as well as Sydney and Melbourne in Australia. He is slated to perform in Macao for three concerts starting June 7. Asked whether shows in Southeast Asia might be canceled due to COVID-19 concerns, his agency Galaxy Corporation told The Korea Herald, 'We don't know at this point.' G-Dragon recently called off his "G-Dragon Media Exhibition: Ubermensch" in Shanghai, which was originally scheduled to run from May 30 to June 22. While the agency cited 'unforeseen circumstances beyond our control' as the reason for the cancellation, the uptick in COVID-19 cases in China is widely suspected as a contributing factor. Babymonster, also on an Asia tour, wrapped up its 'Hello Monsters' concerts in Singapore and Hong Kong in May and is preparing for its final Southeast Asian stop in Bangkok from June 7-8. YG Entertainment confirmed it has no plans to postpone or cancel the shows. 'We're monitoring the situation closely, but the outbreak is limited to certain regions. Everything is proceeding as planned,' a YG official told The Korea Herald on Wednesday. Le Sserafim is scheduled to perform in Taiwan and Hong Kong in July, followed by concerts in the Philippines, Thailand and Singapore in August as part of its 'Easy Crazy Hot' world tour. Source Music's parent company, Hybe, also confirmed that all shows will proceed as scheduled. JYP Entertainment's acts — Niziu, Nmixx and Xdinary Heroes — are also expected to hold small-scale performances in Hong Kong, Macao and Taiwan, respectively, in the second half of the year, with no changes announced. An industry official noted that unless governments issue specific warnings or event restrictions, K-pop agencies are unlikely to take unilateral action regarding concert postponements. 'There aren't any government guidelines like we saw during the height of the pandemic, so it's hard for companies to take preemptive action on their own,' one agency source said. Another industry official echoed the sentiment: 'Without national-level advisories, it's difficult for agencies to make those decisions independently.'
